Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program

Bibliography

• Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008;26:5721–7
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23–30
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905–14
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229–37
   PubMed Web of Science ®Google Scholar
• Ficorella C, Bruera G, Cannita K, et al. Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice. Clin Colorectal Cancer 2012;11:229–37
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, az-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013–19
   PubMed Web of Science ®Google Scholar
• Sobrero A, Ackland S, Clarke S, et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 2009;77:113–19
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539–44
   PubMed Web of Science ®Google Scholar
• Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29–37
   PubMed Web of Science ®Google Scholar
• Grothey A, Flick ED, Cohn AL, et al. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf 2014;23:726–34
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Wiese MD, Rowland A, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 2015;26:13–21
   PubMed Web of Science ®Google Scholar
• Formica V, Roselli M. Targeted therapy in first line treatment of RAS wild type colorectal cancer. World J Gastroenterol 2015;21:2871–4
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757–65
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30:3499–506
   PubMed Web of Science ®Google Scholar
• Tabernero J, Van CE, Lakomy R, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 2014;50:320–31
   PubMed Web of Science ®Google Scholar
• Wang TF, Lockhart AC. Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol 2012;6:19–30
   PubMedGoogle Scholar
• Frassineti L, Di Bartolomeo M, Thomas AL, Taieb J. Aflibercept + FOLFIRI for treatment of metastatic colorectal cancer after oxaliplatin failure: 4th interim safety data from the global aflibercept safety and quality-of-life program (ASQoP/AFEQT studies) [abstract 528P]. Ann Oncol 2014;25:167–209
   Google Scholar
• Bordonaro R, Sobrero AF, Frassineti L, et al. Ziv-aflibercept in combination with FOLFIRI for second-line treatment of patients with metastic colorectal cancer (mCRC): Interim safety sata from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies) in patients >=65. J Clin Oncol 2014;32(Suppl 3):abstract 545
   Google Scholar
• Ferry DR, Sobrero AF, Bordonaro R, et al. Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B). J Clin Oncol 2014;32(Suppl 3):abstract 556
   Google Scholar
• Sobrero AF, Bordonaro R, Bencardino K, et al. Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B). J Clin Oncol 2015;33(Suppl 3)):abstract 528
   Google Scholar
• Ruff P, Ferry DR, Lakomy R, et al. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. Eur J Cancer 2015;51:18–26
   PubMed Web of Science ®Google Scholar